An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 6, 2005, Pages 842-848

  Dorrance, Anne M ^a,b   Rupp, Nicole ^a   Pollock, David M ^a,b   Newman, John W ^b   Hammock, Bruce D ^b   Imig, John D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epoxyeicosatrienoic acids; Hypertension; Ischemia; Soluble expoxide hydrolase

Indexed keywords

12 (3 ADAMANTAN 1 YLUREIDO)DODECANOIC ACID; ALCOHOL DERIVATIVE; EPOXIDE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; FATTY ACID; HYDROLASE INHIBITOR; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; 12-(3-ADAMANTAN-1-YLUREIDO)DODECANOIC ACID; ADAMANTANE; DRUG DERIVATIVE; ENZYME INHIBITOR; LAURIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOGRAPHY; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL FUNCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PROTECTION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; FATTY ACID METABOLISM; HEART PROTECTION; HEMISPHERE; HYPERTENSION; INSTRUMENT; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; RISK FACTOR; SPONTANEOUSLY HYPERTENSIVE RAT; TELEMETRY; URINARY EXCRETION; ANIMAL; BLOOD; BRAIN INFARCTION; DRUG ANTAGONISM; METABOLISM;

ADAMANTANE; ANIMALS; BRAIN ISCHEMIA; CEREBRAL INFARCTION; ENZYME INHIBITORS; EPOXIDE HYDROLASES; EPOXY COMPOUNDS; HYPERTENSION; LAURIC ACIDS; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED SHR;

EID: 33644697099     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000189600.74157.6d     Document Type: Article

References (37)

1. Coyle P, Jokelainen PT. Differential outcome to middle cerebral artery occlusion in spontaneously hypertensive rats (SHRSP) and Wistar-Kyoto (WKY) rats. Stroke. 1983;14:605-611.
2. Coyle P, Heistad DD. Blood flow through cerebral and collateral vessels one month after middle cerebral artery occlusion. Stroke. 1987;18:407-411.
3. Zhao X, Yamamoto T, Newman JW, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004;15:12442-12445.
4. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000;87:992-998.
5. Davis BB, Thompson DA, Howard LL, et al. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA. 2002;99:2222-2227.
6. Schmelzer KR, Kubala L, Newman JW, et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA. 2005;102:9772-9777.
7. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001;276:36059-36062.
8. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 2000;41:163-181.
9. Spector AA, Fang X, Snyder GD, et al. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res. 2004;43:55-90.
10. Ellis EF, Police RJ, Yancey L, et al. Dilation of cerebral arterioles by cytochrome P-450 metabolites of arachidonic acid. Am J Physiol. 1990;259:H1171-H1177.
11. Leffler CW, Fedinec AL. Newborn piglet cerebral microvascular responses to epoxyeicosatrienoic acids. Am J Physiol. 1997;273:H333-H338.
12. Zhang C, Harder DR. Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic Acid. Stroke. 2002;33:2957-2964.
13. Gebremedhin D, Ma YH, Falck JR, et al. Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am J Physiol. 1992;263:H519-H525.
14. Harder DR, Zhang C, Gebremedhin D. Astrocytes function in matching blood flow to metabolic activity. News Physiol Sci. 2002;17:27-31.
15. Watanabe T, Morisseau C, Newman JW, et al. In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecylurea. Drug Metab Dispos. 2003;31:846-853.
16. Kim IH, Morisseau C, Watanabe T, et al. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem. 2004;47:2110-2122.
17. Newman JW, Watanabe T, Hammock BD. The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res. 2002;43:1563-1578.
18. Sasser JM, Pollock JS, Pollock DM. Renal endothelin in chronic angiotensin II hypertension. Am J Physiol. 2002;283:R243-R248.
19. Zea Longa E, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84-91.
20. Dorrance AM, Osborn HL, Grekin R, et al. Spironolactone reduces cerebral infarct size and epidermal growth factor receptor mRNA in stroke-prone rats. Am J Physiol. 2001;281:R944-R950.
21. Baumbach GL, Hajdu MA. Mechanics and composition of cerebral arterioles in renal and spontaneously hypertensive rats. Hypertension. 1993;21:816-826.
22. Cipolla MJ, Curry AB. Middle cerebral artery function after stroke: the threshold duration of reperfusion for myogenic activity. Stroke. 2002;33:2094-2099.
23. Imig JD, Zhao X, Capdevila JH, et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39:690-694.
24. Fornage M, Hinojos CA, Nurowska BW, et al. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 2002;40:485-490.
25. Imig JD, Zhao X, Pollock DM, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2003;42:395.
26. Alkayed NJ, Narayanan J, Gebremedhin D, et al. Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke. 1996;27:971-979.
27. Murphy S, Pearce B, Jeremy J, et al. Astrocytes as eicosanoid-producing cells. Glia. 1988;1:241-245.
28. Temburni MK, Jacob MH. New functions for glia in the brain. Proc Natl Acad Sci USA. 2001;98:3631-3632.
29. Araque A, Carmignoto G, Haydon PG. Dynamic signaling between astrocytes and neurons. Annu Rev Physiol. 2001;63:795-813.
30. Alkayed NJ, Birks EK, Narayanan J, et al. Role of P-450 arachidonic acid epoxygenase in the response of cerebral blood flow to glutamate in rats. Stroke. 1997;28:1066-1072.
31. + channels and p42/p44 MAPK pathway. Circ Res. 2004;95:506-514.
32. Sellers KW, Sun C, Diez-Freire C, et al. Novel mechanism of brain epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB J. 2005;19:626-628.
33. Weintraub NL, Fang X, Kaduce TL, et al. Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am J Physiol. 1999;277:H2098-H2108.
34. Fang X, Kaduce TL, Weintraub NL, et al. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem. 2001;276:14867-14874.
35. Fang X, Weintraub NL, McCaw RB, et al. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol. 2004;287:H2412-H2420.
36. Fang X, Hu S, Watanabe T, et al. Activation of peroxisome proliferator-activated receptor a by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther. 2005;314:260-270.
37. Deplanque D, Gele P, Petrault O, et al. Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003;23:6264-6271.